The surgical robot developer will use the series B financing, co-led by SinoPharm, to support it through its application for market clearance.

The Warwick spinout has received $5.1m in capital from investors such as Mercia Technologies to fund commercialisation of a transdermal ibuprofen patch.

NEA has led a series B round for cancer treatment developer Pionyr Immunotherapeutics, co-founded by researchers from UC San Francisco and University of Toronto.

Satt Sud-Est has licensed technology relating to metamaterial-based antennae for very powerful MRI scanners to Multiwave Innovation.

The ocular biotech spinout was has received cash from backers including the VTC Innovation Fund as it prepares to take its dry eye syndrome treatment through clinical testing.

Existing shareholders have provided additional funding to Abingdon Health, which is developing a test for multiple myeloma.

ETH Zurich spinout Spirochem has raised cash to accelerate its sales activities and boost productivity.

NorthSea Therapeutics has secured $29.3m in series A funding to continue development of treatments for inflammatory and liver diseases.

The company is working on treatments for breast cancer and solid tumours, based on research at University of Toronto and the Centre for the Commercialization of Antibodies and Biologics.